FDA Accepts Merck ’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
KENILWORTH, N.J.--(BUSINESS WIRE)-- September 17, 2019 -- Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 17, 2019 Category: Pharmaceuticals Source Type: clinical trials
GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute
London/Washington, D.C. 06 August 2019 -- GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 6, 2019 Category: Pharmaceuticals Source Type: clinical trials
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Condition: Ebola Virus Intervention: Biological: cAd3-EBO S vaccine Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); US Military HIV Research Program Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials
